Skip to main content
. 2019 Jan 10;9:30. doi: 10.1038/s41598-018-37188-0

Figure 1.

Figure 1

BRAFV600E mutant T24.6.9 and wild type T12.8.10 melanoma cells are characterised by comparable melanoma characteristics but respond highly differently to BRAF inhibitor PLX4032 and chemotherapeutics dacarbazine and cisplatin. (A) Immunocytochemical staining of melanoma markers HMB45, MelanA and S100 as well as adhesion molecules E-Cadherin (E-Cadh) and MelCAM in human melanoma cells T24.6.9 and T12.8.10 (bar = 50 µm). (B) Flow cytometric analysis of proliferative and apoptotic cell populations (after 72 h treatment). Drug effects are displayed by logarithmised IC50 values. Effects of increasing concentrations of PLX4032 on T24.6.9 (C) and T12.8.10 (D) cells after 96 hours treatment (left: microscopic images (bars = 200 µm); middle: immunoblots). Quantification of active ERK (pERK) after 48 and 96 hours (right). Values are normalised to GAPDH expression and untreated control (dashed line, 100%). The blots were cropped to focus upon the specific proteins indicated. The entire gel blots are shown in Supplementary Figure S5. (n values depicted in figure; mean ± s.e.m.; **P < 0.01; ***P < 0.001); Dacarb = dacarbazine; cisPt = cisplatin; p = phosphorylated.